The Toxicology Investigators Consortium Case Registry—the 2014 Experience

被引：15

作者：

Rhyee S.H. ^{[1
]}

Farrugia L. ^{[2
]}

Campleman S.L. ^{[3
]}

Wax P.M. ^{[3
,4
]}

Brent J. ^{[5
]}

机构：

[1] University of Massachusetts Medical School, 55 Lake Avenue North, LA-202, Worcester, 01655, MA

[2] Hartford Hospital, 80 Seymour Street, Hartford, 06102, CT

[3] American College of Medical Toxicology, 10645 N. Tatum Blvd., Suite 200-111, Phoenix, 85028, AZ

[4] UT Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, 75390, TX

[5] Toxicology Associates, 2555 South Downing Street, Denver, 80210, CO

来源：

Journal of Medical Toxicology | 2015年 / 11卷 / 4期

基金：

美国国家卫生研究院;

关键词：

Epidemiology; Overdose; Poisonings; Surveillance;

D O I：

10.1007/s13181-015-0507-7

中图分类号：

学科分类号：

摘要：

The Toxicology Investigators Consortium (ToxIC) Case Registry was established in 2010 by the American College of Medical Toxicology. The Registry includes all medical toxicology consultations performed at participating sites. The Registry was queried for all cases entered between January 1 and December 31, 2014. Specific data reviewed for analysis included demographics (age, gender, ethnicity), source of consultation, reasons for consultation, agents involved in toxicological exposures, signs, symptoms, clinical findings, fatalities, and treatment. In 2014, 9172 cases were entered in the Registry across 47 active member sites. Females accounted for 51.1 % of cases. The majority (65.1 %) of cases were adults between the ages of 19 and 65. Caucasians made up the largest identified ethnic group (48.9 %). Most Registry cases originated from the inpatient setting (93.5 %), with a large majority of these consultations coming from the emergency department or inpatient admission services. Intentional and unintentional pharmaceutical exposures continued to be the most frequent reasons for consultation, accounting for 61.7 % of cases. Among cases of intentional pharmaceutical exposure, 62.4 % were associated with a self-harm attempt. Non-pharmaceutical exposures accounted for 14.1 % of Registry cases. Similar to the past years, non-opioid analgesics, sedative-hypnotics, and opioids were the most commonly encountered agents. Clinical signs or symptoms were noted in 81.9 % of cases. There were 89 recorded fatalities (0.97 %). Medical treatment (e.g., antidotes, antivenom, chelators, supportive care) was rendered in 62.3 % of cases. Patient demographics and exposure characteristics in 2014 Registry cases remain similar to prior years. The majority of consultations arose in the acute care setting (emergency department or inpatient) and involved exposures to pharmaceutical products. Among exposures, non-opioid analgesics, sedative/hypnotics, and opioids were the most frequently encountered. A majority of cases required some form of treatment, but fatalities were rare. © 2015, American College of Medical Toxicology.

引用

页码：388 / 409

页数：21

共 8 条

[1]

Wax P.M., Kleinschmidt K.C., Brent J., The Toxicology Investigators Consortium (ToxIC) Registry, J Med Toxicol, 7, 4, pp. 259-265, (2011)

[2]

Brent J., Wax P.M., Schwartz T., Et al., The Toxicology Investigators Consortium Case Registry—the 2010 experience, J Med Toxicol, 7, 4, pp. 266-276, (2011)

[3]

Wiegand T.J., Wax P.M., Schwartz T., Et al., The Toxicology Investigators Consortium Case Registry—the 2011 experience, J Med Toxicol, 8, 4, pp. 360-377, (2012)

[4]

Wiegand T., Wax P., Smith E., Et al., The Toxicology Investigators Consortium Case Registry—the 2012 experience, J Med Toxicol, 9, 4, pp. 380-404, (2013)

[5]

Rhyee S.H., Farrugia L., Wiegand T., Smith E.A., Wax P.M., Brent J., on behalf of the Toxicology Investigators Consortium, The Toxicology Investigators Consortium Case Registry—the 2013 experience, J Med Toxicol, 10, 4, pp. 342-359, (2014)

[6]

Blake A., Froberg B.A., Levine M., Beuhler M.C., Judge B.S., Moore P.W., Et al., Acute methylenedioxypyrovalerone toxicity, J Med Toxicol, (2014)

[7]

Watkins J.W., Schwarz E.S., Arroyo-Plasencia A.M., Mullins M.E., on behalf of the Toxicology Investigators Consortium, The use of physostigmine by toxicologists in anticholinergic toxicity, J Med Toxicol, (2014)

[8]

Neavyn M.J., Suicide and the surrogate, J Med Toxicol, 10, 1, pp. 3-6, (2014)

← 1 →